Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
XILOAnnounced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy
August 14, 2025Clinical Trials
Read more →